Revance Therapeutics Inc (NASDAQ:RVNC)
| 13.53 Delayed Data As of 3:59pm ET |  -0.48 / -3.43%Today’s Change | 13.01 Today|||52-Week Range 33.83 | -52.26% Year-to-Date |
Latest RVNC News | Press Releases
| Zazove Associates Llc Buys Akamai Technologies Inc, Liberty Media Acquisition Corp, Pioneer ... Oct 25 / GuruFocus News - Paid Partner Content | Why Revance Therapeutics Stock Is Getting Crushed Today Oct 18 / MotleyFool.com - Paid Partner Content |
| These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday Oct 18 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 14.01 |
| Today’s open | 13.96 |
| Day’s range | 13.35 - 13.97 |
| Volume | 36,753 |
| Average volume (3 months) | 836,831 |
| Market cap | $1.1B |
Data as of 3:59pm ET, 10/27/2021
Growth & Valuation
| Earnings growth (last year) | -32.56% |
| Earnings growth (this year) | +12.04% |
| Earnings growth (next 5 years) | +192.00% |
| Revenue growth (last year) | +3,610.65% |
| P/E ratio | NM |
| Price/Sales | 107.27 |
| Price/Book | 2.85 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VNDAVanda Pharmaceutical... | -0.15 | -0.83% |
| ---- | ||
| ENDPEndo International P... | -0.17 | -3.89% |
| ACRSAclaris Therapeutics... | +0.08 | +0.50% |
Data as of 4:47pm ET, 10/27/2021
Financials
| Next reporting date | November 4, 2021 |
| EPS forecast (this quarter) | -$0.97 |
| Annual revenue (last year) | $15.3M |
| Annual profit (last year) | -$282.1M |
| Net profit margin | -1,840.71% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Nashville, Tennessee |
Forecasts
